Adagene Inc banner

Intrinsic Value

The intrinsic value of Adagene Inc (978) under the Base Case is 0.004 EUR per share. Compared with the current market price of 1.39 EUR, the stock appears Overvalued by 100% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

Intrinsic Value
€0.004
Overvaluation 100%
Intrinsic Value
Price €1.39
Alert me when Adagene Inc is below its intrinsic value
Today €0.00 · 99.8% below the current price

Adagene Inc is more expensive than usual. It was this expensive or more expensive on less than 1% of days in the past 5 years.

Alternatives to Adagene Inc

Fundamental Analysis

What Adagene Does

Biotechnology Health Care

Adagene is a biotechnology company that designs and develops antibody-based cancer medicines. Its main work is to create therapeutic antibodies and move the most promising ones into clinical testing, rather than selling a finished drug portfolio today. The company’s science centers on making antibodies that are active only when they reach the right tumor environment, which is meant to improve how the drugs target cancer cells.

Headquarters
China CN
Employees
128
IPO date
Feb 9, 2021
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Adagene insiders rarely trade

Insider trading · Last trade on Sep 23, 2026

Sold $0 Nobody sold
Bought $162.2k 3 insiders
Trades by date
Open insider trading

Past 12 months

Continue Research

Decided on Adagene? Get an email when Adagene Inc reaches the price you’d buy at. Free with an account.

Other Adagene listings

What is the Intrinsic Value of one Adagene Inc stock?

The intrinsic value for Adagene Inc (978) under the Base Case is 0.004 EUR.

Is Adagene Inc stock undervalued or overvalued?

Compared with the current market price of 1.39 EUR, the stock appears Overvalued by 100% .

How reliable are our estimates? See how past valuations played out
Back to Top